Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tripathy

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2020
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalM J M Magbanua, L B Swigart, H-T Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2020
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalM J M Magbanua, L B Swigart, H-T Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Pageof 7